AI Insight
This study reveals that red blood cells (RBCs) capture and retain tumor-derived DNA on their surface, creating a distinct pool of circulating tumor DNA separate from plasma. The researchers found that RBC surface properties, specifically sialylation levels and TLR9 receptors, regulate DNA binding capacity. In both mouse models and human lung cancer patients, RBC-bound tumor DNA was more abundant and detectable than plasma-based tumor DNA, with mutations matching those found in tumor tissue.
Why it matters
This discovery challenges the current approach to liquid biopsy, which focuses exclusively on plasma for detecting circulating tumor DNA. Using RBCs as a source could significantly improve cancer detection sensitivity and monitoring, potentially enabling earlier diagnosis and better tracking of treatment response in cancer patients.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Red blood cells (RBCs) modulate host inflammatory responses by scavenging mitochondrial and pathogen DNA. However, how RBC surface properties govern the capture of tumor-derived DNA remains poorly understood. We show that RBCs tether and retain tumor-derived DNA on their surface, forming a distinct circulating pool of RBC-bound tumor DNA (rtDNA). Desialylation increased DNA capture in a Toll-like receptor 9 (TLR9)-dependent manner, identifying RBC surface sialylation and TLR9 as a regulator of DNA binding. In mice bearing lung cancer xenografts, rtDNA was detected in all animals and its abundance correlated with tumor burden, whereas tumor DNA was undetectable in matched plasma samples. In patients with lung cancer, the majority of detected mutant tumor DNA was associated with RBCs rather than plasma, and RBC-derived mutations were concordant with molecular alterations identified in matched tumor tissue. Collectively, these findings establish the RBC surface as a tunable site of tumor-DNA capture and retention and challenge the plasma-centric paradigm of liquid biopsy by identifying a distinct cellular reservoir of tumor-derived genetic material.
Source: The Red Blood Cell Surface Defines a Distinct Tumor DNA Compartment for Liquid Biopsy